RESUMEN
The concept of psoriatic arthritis (PsA) prevention is gaining increased interest owing to the physical limitation, poor quality of life and low remission rates that are achieved with current therapies for PsA. The psoriasis-to-PsA transition offers a unique opportunity to identify individuals at increased risk of developing PsA and to implement preventive strategies. However, identifying individuals at increased risk of developing PsA is challenging as there is no consensus on how this population should be defined. This Consensus Statement puts forward recommended terminology from the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) for defining specific subgroups of individuals during the preclinical and early clinical phases of PsA to be used in research studies. Following a three-round Delphi process, consensus was reached for three terms and definitions: 'increased risk for PsA', 'psoriasis with asymptomatic synovio-entheseal imaging abnormalities' and 'psoriasis with musculoskeletal symptoms not explained by other diagnosis'. These terms and their definitions will enable improved identification and standardization of study populations in clinical research. In the future, as increasing evidence emerges regarding the molecular and clinical features of the psoriasis-to-PsA continuum, these terms and definitions will be further refined and updated.
Asunto(s)
Artritis Psoriásica/tratamiento farmacológico , Artritis Psoriásica/prevención & control , Evaluación Preclínica de Medicamentos/ética , Psoriasis/terapia , Artritis Psoriásica/diagnóstico , Artritis Psoriásica/psicología , Consenso , Técnica Delphi , Personas con Discapacidad/psicología , Evaluación Preclínica de Medicamentos/métodos , Femenino , Humanos , Masculino , Psoriasis/complicaciones , Psoriasis/diagnóstico , Psoriasis/epidemiología , Calidad de Vida , Medición de Riesgo , Terminología como AsuntoRESUMEN
OBJECTIVES: Contemporary biologic therapies for psoriasis are independently licensed for psoriatic arthritis (PsA). Since skin disease generally predates PsA and PsA has a subclinical phase, we investigated the pattern of PsA evolution in psoriasis treated with biologic agents compared to other medications including oral therapy, topical agents or no treatments. METHODS: A retrospective chart review was performed in psoriasis patients with musculoskeletal symptoms referred for rheumatological assessment. Patients who had a final diagnosis of PsA were identified. The frequency and clinical features of PsA were compared for biologics versus the other strategies. RESULTS: Between 2015-18, 203 psoriasis patients were referred for musculoskeletal symptoms with 25 on biologics, 31 on non-biologic systemic therapies and 147 on topical/no therapies. A final diagnosis of PsA was similar in all groups (biologics: 36%; non-biologic systemic treatments: 35.4%; none/local treatments: 37.4%). Most patients had musculoskeletal symptoms before systemic therapy initiation but new onset PsA was evident in 12% (3/25) biologics treated patients, 9.6% (3/31) in non-biologic systemic therapy patients and was significantly higher in patients on topical/no therapy (55/147; 37.4%, p<0.001). Among patients with PsA, none of the patients on biologics exhibited dactylitis compared to 28.6% of other systemic treatments and 48.6% of none/local treatments (p=0.046). CONCLUSIONS: New symptoms and signs leading to PsA diagnosis appear to decrease with systemic treatments. The characteristic PsA dactylitis lesion was not evident in the biologic therapy group.
Asunto(s)
Artritis Psoriásica , Productos Biológicos , Psoriasis , Anticuerpos Monoclonales/uso terapéutico , Artritis Psoriásica/epidemiología , Artritis Psoriásica/prevención & control , Terapia Biológica , Humanos , Inmunosupresores/uso terapéutico , Psoriasis/epidemiología , Psoriasis/terapia , Estudios RetrospectivosAsunto(s)
Ácidos Grasos Omega-3/administración & dosificación , Ácidos Grasos Omega-6/administración & dosificación , Psoriasis/prevención & control , Adulto , Artritis Psoriásica/dietoterapia , Artritis Psoriásica/prevención & control , Productos Pesqueros/estadística & datos numéricos , Humanos , Estudios Prospectivos , Psoriasis/dietoterapia , Factores de RiesgoRESUMEN
No disponible
Asunto(s)
Humanos , Psoriasis/epidemiología , Psoriasis/prevención & control , Artritis Psoriásica/epidemiología , Artritis Psoriásica/prevención & control , Investigación/organización & administración , Investigación/tendencias , Terapia Biológica/métodos , Terapia Biológica/tendencias , Certolizumab Pegol/uso terapéutico , Psoriasis/economía , Inflamación/epidemiología , Inflamación/inmunología , Inflamación/prevención & controlRESUMEN
No disponible